Plasma coagulation factor VII (FVII), FIX and FX have been shown to be effective antibacterial proteins against drug-resistant gram-negative bacteria and may offer alternative strategies for combating the increasingly urgent global health threat posed by those resistant pathogens. Read More
The FDA cleared Rozlytrek (entrectinib) for the treatment of adults with ROS1-positive, metastatic non-small-cell lung cancer, also granting accelerated approval to the tyrosine kinase inhibitor for adult and pediatric patients (12 and older) with solid tumors that have a NTRK gene fusion. Read More
HONG KONG – Following a regulatory committee's ruling that three of four deaths previously reported during a phase II trial were unrelated to the study drug, South Korea's Ministry of Food and Drug Safety (MFDS) cleared Yuhan Corp. to continue testing lazertinib (YH-25448) in the non-small-cell lung cancer (NSCLC) study. Read More
HONG KONG – South Korean biotech venture Crystal Genomics Inc., based in Seongnam City, Gyeonggi-do, said it signed a memorandum of understanding for a strategic partnership with Bellevue Asset Management AG, a global asset manager headquartered in Küsnacht, Switzerland. Read More
RIYADH, Saudi Arabia – Saudi Arabia, a country best known as one of the world's largest oil producers, is looking to develop a stronger domestic biotech and pharmaceutical industry, partly to diversify its economy and partly to address its domestic health care needs. Read More
BEIJING – Look out, Hong Kong Stock Exchange (HKEX). Chinese pre-profit biotech startups are now starting to apply for listing on Shanghai's sci-tech innovation board known as the STAR, with the latest application filed by HIV drugmaker Frontier Biotechnologies Inc., of Nanjing. Read More
